Neil Gibson

1.7k total citations
35 papers, 851 citations indexed

About

Neil Gibson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Neil Gibson has authored 35 papers receiving a total of 851 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Neil Gibson's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (7 papers) and HER2/EGFR in Cancer Research (5 papers). Neil Gibson is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (7 papers) and HER2/EGFR in Cancer Research (5 papers). Neil Gibson collaborates with scholars based in United Kingdom, Germany and United States. Neil Gibson's co-authors include Gordon A. Leonard, William P. Watson, William N. Hunter, Katherine E. McAuley-Hecht, Tom Brown, James B. Thomson, Suzanne Jenkins, Charles R. Newton, Stephen F. Little and Giulia C. Kennedy and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Biochemistry.

In The Last Decade

Neil Gibson

34 papers receiving 835 citations

Peers

Countries citing papers authored by Neil Gibson

Since Specialization

Citations

This map shows the geographic impact of Neil Gibson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Gibson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Gibson more than expected).

Fields of papers citing papers by Neil Gibson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Gibson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Gibson. The network helps show where Neil Gibson may publish in the future.

Co-authorship network of co-authors of Neil Gibson

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Gibson. A scholar is included among the top collaborators of Neil Gibson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Gibson. Neil Gibson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib 2022 ·OncoTargets and Therapy ·Scott Owen, (unknown), Jad Alshami, Marie‐Christine Guiot, Petr Kavan, David A. Reardon, Thierry Muanza, Neil Gibson, (unknown), Flavio Solca, A. Cseh, Frank Saran	2
2	A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors. 2019 ·Journal of Clinical Oncology ·Curtis R. Chong, Todd M. Bauer, Scott A. Laurie, Manish R. Patel, Noboru Yamamoto, (unknown), (unknown), Neil Gibson, Markus Vallaster, Patricia LoRusso	3
3	Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung 2018 ·OncoTargets and Therapy ·Shun Lü, Wěi Li, Caicun Zhou, Chengping Hu, Shukui Qin, Gang Cheng, Jifeng Feng, Jie Wang, A. Cseh, Barbara Peil, Neil Gibson, E. Ehrnrooth, Li Zhang	7
4	Phase II trial of afatinib in patients with advanced/metastatic urothelial carcinoma (UC) with genetic alterations in ERBB receptors 1-3 who failed on platinum-based chemotherapy (CT). 2018 ·Journal of Clinical Oncology ·Albert Font Pous, Javier Puente, Daniel Castellano, Francisco X. Real, Miguel Ángel Climent, (unknown), Stéphane Oudard, (unknown), Rafael Morales‐Barrera, (unknown), Núria Sala, Begoña Pérez‐Valderrama, Xavier García del Muro, Pedro L. Fernández, Pedro Jares, Ibán Aldecoa, Neil Gibson, (unknown), (unknown), Begoña Mellado	4
5	Afatinib in patients with advanced or metastatic urothelial carcinoma (UC) with genetic alterations in ErbB receptors 1–3 who failed on platinum-based chemotherapy: The Phase II LUX-Bladder 1 trial 2017 ·Annals of Oncology ·Albert Font, Francisco X. Real, Javier Puente, (unknown), Núria Sala, Juan Antonio Virizuela, Alejo Rodríguez‐Vida, Enrique Grande Pulido, Daniel Castellano, José A. Martínez-Climent, (unknown), Aranzazu González del Alba, Pedro L. Fernández, Pedro Jares, Ibán Aldecoa, Neil Gibson, (unknown), (unknown), E. Ehrnrooth, Begoña Mellado	2
6	P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung 2017 ·Journal of Thoracic Oncology ·Glenwood Goss, Enriqueta Felip, Manuel Cobo, Shun Lü, (unknown), K.H. Lee, Erdem Göker, Vassilis Georgoulias, W. Li, (unknown), Dolores Isla, Young Joo Min, Alessandro Morabito, Andrea Ardizzoni, Shirish M. Gadgeel, Neil Gibson, Nicole Krämer, Flavio Solca, A. Cseh, E. Ehrnrooth, Jean‐Charles Soria	2
7	Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung 2016 ·Annals of Oncology ·Glenwood Goss, K.H. Lee, Enriqueta Felip, Manuel Cobo, (unknown), Erdem Göker, (unknown), (unknown), Dolores Isla, Young Joo Min, Alessandro Morabito, Nicholas Dupuis, Vikram K. Chand, Flavio Solca, Nicole Krämer, Neil Gibson, E. Ehrnrooth, J.C. Soria	1
8	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 2016 ·British Journal of Cancer ·Yi‐Long Wu, Lecia V. Sequist, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wei Li, Mei Hou, Martin Schüler, Tony Mok, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Neil Gibson, Dan Massey, Miyoung Kim, James Chih‐Hsin Yang	70
9	Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine 2016 ·PLoS Medicine ·Gerald Goh, Ramona Schmid, (unknown), Wichit Arpornwirat, Imjai Chitapanarux, Vinod Ganju, Seock‐Ah Im, Sung‐Bae Kim, Arunee Dechaphunkul, (unknown), Neil L. Spector, Thomas Yau, (unknown), Slim Ben Ahmed, Stephen Johnston, Neil Gibson, Martina Uttenreuther‐Fischer, Javier Herrero, Charles Swanton	26
10	Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, phase 3 LUX-Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second-line treatment of advanced squamous cell carcinoma (SCC) of the lung. 2016 ·Journal of Clinical Oncology ·Glenwood Goss, Ki Hyeong Lee, Enriqueta Felip, Manuel Cobo, Konstantinos N. Syrigos, Erdem Göker, Vassilis Georgoulias, Salih Zeki Güçlü, Dolores Isla, Young Joo Min, Alessandro Morabito, Sandra Close, Nicholas Dupuis, Vikram K. Chand, Flavio Solca, Nicole Krämer, Neil Gibson, E. Ehrnrooth, Jean‐Charles Soria	2
11	Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report 2015 ·Oncotarget ·Jad Alshami, Marie‐Christine Guiot, Scott Owen, Petr Kavan, Neil Gibson, Flavio Solca, A. Cseh, David A. Reardon, Thierry Muanza	16
12	RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib 2013 ·PLoS ONE ·James Bradford, Matthew R. Farren, Steve Powell, Sarah Runswick, Susie Weston, Helen Brown, Oona Delpuech, Mark Wappett, Neil R. Smith, T. Hedley Carr, Jonathan R. Dry, Neil Gibson, Simon T. Barry	24
13	Metastatic osteosarcoma to the stomach and ascending colon in a pediatric patient causing gastrointestinal hemorrhage 2013 ·Journal of Pediatric Surgery ·Jonathan Moses, Neil Gibson, Thomas Plesec, Gregory E. Plautz, Marsha Kay, Oliver S. Soldes	7
14	The use of real-time PCR methods in DNA sequence variation analysis 2005 ·Clinica Chimica Acta ·Neil Gibson	87
15	Novel Technology and the Development of Pharmacogenetics within the Pharmaceutical Industry 2005 ·Pharmacogenomics ·Neil Gibson, (unknown), Ruth March	7
16	Whole-Genome Scan, in a Complex Disease, Using 11,245 Single-Nucleotide Polymorphisms: Comparison with Microsatellites 2004 ·The American Journal of Human Genetics ·Sally John, Neil Shephard, Guoying Liu, Eleftheria Zeggini, Manqiu Cao, Wei‐Wen Chen, Nisha Vasavda, Tracy Mills, Anne Barton, Anne Hinks, Stephen Eyre, Keith Jones, William Ollier, Alan J. Silman, Neil Gibson, Jane Worthington, Giulia C. Kennedy	174
17	High‐throughput SNP genotyping 2002 ·Comparative and Functional Genomics ·Suzanne Jenkins, Neil Gibson	56
18	A Colorimetric Assay for Phosphate to Measure Amplicon Accumulation in Polymerase Chain Reaction 1997 ·Analytical Biochemistry ·Neil Gibson, Charles R. Newton, Stephen F. Little	23
19	Crystal Structure of a DNA Duplex Containing 8-Hydroxydeoxyguanine-Adenine Base Pairs 1994 ·Biochemistry ·Katherine E. McAuley-Hecht, Gordon A. Leonard, Neil Gibson, James B. Thomson, William P. Watson, William N. Hunter, Tom Brown	201
20	Guanine-1,N6-Ethenoadenine Base Pairs in the Crystal Structure of d(CGCGAATT(.epsilon.dA)GCG) 1994 ·Biochemistry ·Gordon A. Leonard, Katherine E. McAuley-Hecht, Neil Gibson, Tom Brown, William P. Watson, William N. Hunter	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact